Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Fireman B.V. (IFRX)

Fireman B.V. (IFRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
InflaRx N.V. Receives Positive CHMP Opinion for Marketing Authorization of GOHIBIC for COVID-19 Linked Acute Respiratory Distress Syndrome Treatment

The CHMP recommends marketing authorization for InflaRx's GOHIBIC to treat COVID-19 related ARDS in certain patients.Quiver AI SummaryInflaRx N.V. announced that the Committee for Medicinal Products for...

IFRX : 2.06 (+0.98%)
WuXi Biologics Announces Manufacturing Partnership with InflaRx to Advance Gohibic for the Treatment of Certain Critically Ill COVID-19 patients

/PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced the...

IFRX : 2.06 (+0.98%)
Stock Index Futures Move Higher Ahead of U.S. Inflation Data, Fed Minutes

June S&P 500 futures (ESM23) are up +0.28%, and June Nasdaq 100 E-Mini futures (NQM23) are up +0.21% this morning after three major U.S. benchmark indices finished the regular session mixed as market participants...

ESM23 : 4,453.35s (+0.61%)
NQM23 : 15,316.61s (+0.85%)
CAT : 389.59 (+2.12%)
VOLVB.S.DX : 267.000 (-0.93%)
HTCR : 1.3000 (+4.84%)
HZON : 11.33 (+0.09%)
CFLT : 30.61 (+7.14%)
IFRX : 2.06 (+0.98%)
MDB : 315.44 (+11.95%)
Why InflaRx Stock Skyrocketed This Week

The biopharmaceutical company's near-term sales outlook has gotten a huge boost following Emergency Use Authorization for one of its drugs.

RJF : 163.78 (+0.99%)
IFRX : 2.06 (+0.98%)
Why Shares of InflaRx Are Soaring Wednesday

A key EUA from the FDA for the company's COVID-19 therapy gave the stock a jolt.

IFRX : 2.06 (+0.98%)
Stock Index Futures Move Lower as Recession Fears Weigh on Sentiment

June S&P 500 futures (ESM23) are down -0.22%, and June Nasdaq 100 E-Mini futures (NQM23) are down -0.23% this morning after three major U.S. benchmark indices finished the regular session lower as a swathe...

ESM23 : 4,453.35s (+0.61%)
NQM23 : 15,316.61s (+0.85%)
CAT : 389.59 (+2.12%)
JPM : 244.76 (+1.65%)
SW.FP : 80.200 (-0.06%)
KRUS : 95.54 (+7.19%)
IFRX : 2.06 (+0.98%)
JNJ : 155.50 (+1.56%)
SGH : 20.85 (+0.43%)
BE : 23.94 (-3.47%)
CI : 330.07 (+2.07%)
InflaRx Reports Second Quarter 2022 Financial & Operating Results

Fast Track and Orphan Drug designation for vilobelimab in pyoderma gangrenosum (PG) granted by the FDAPlans to submit EUA with the FDA for vilobelimab in...

IFRX : 2.06 (+0.98%)
InflaRx Announces Plans to Apply for Emergency Use Authorization from the US FDA for Vilobelimab for Treatment of Critically Ill COVID-19 Patients

Completed encouraging Type B meeting with US FDAApplication for EUA planned to be submitted in Q3 2022 JENA, Germany, July 26, 2022 (GLOBE NEWSWIRE) --...

IFRX : 2.06 (+0.98%)
InflaRx Receives FDA Fast Track Designation for Treatment of Ulcerative Pyoderma Gangrenosum

US Food and Drug Administration awards Fast Track designation for the treatment of ulcerative pyoderma gangrenosumFast track follows recently reported...

IFRX : 2.06 (+0.98%)
InflaRx Provides Development Update for Vilobelimab in Pyoderma Gangrenosum and Severe COVID-19

Orphan Drug Designation granted for treatment of pyoderma gangrenosum (PG) from US FDA and EMAProductive end-of-phase II meeting with FDA held for PG;...

IFRX : 2.06 (+0.98%)

Barchart Exclusives

1 AI Stock to Buy and Hold for Long-Term Growth
Pure Storage stands out in AI data storage, bolstered by a new partnership with CoreWeave and a solid financial track record, making it an intriguing stock for AI-focused investors Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar